Literature DB >> 18081437

Polymorphisms in TGFbeta and TNFalpha are associated with the myelodysplastic syndrome phenotype.

Martin P Powers1, Ha Nishino, Yamin Luo, Alina Raza, Amulya Vanguri, Lawrence Rice, Youli Zu, Chung-Che Jeff Chang.   

Abstract

CONTEXT: Myelodysplastic syndromes (MDSs) are characterized by ineffective hematopoiesis, excessive apoptosis, and the aberrant expression of a number of cytokines. The genes encoding these cytokines are significantly polymorphic. It is unknown whether these cytokine polymorphisms are associated with, and may therefore be playing a role in the pathogenesis of, MDS.
OBJECTIVE: To determine if certain polymorphisms in the tumor necrosis factor alpha (TNF-alpha) and transforming growth factor beta (TGF-beta) cytokines are overrepresented in a cohort of patients with MDSs.
DESIGN: DNA was isolated from the peripheral blood or bone marrow aspirate of 21 patients with MDS. The genotypes for 4 different polymorphisms, 2 in TNFalpha and 2 in TGFbeta1, were determined using single-specific-primer polymerase chain reaction. The allele and genotype frequencies were compared with similar populations in the National Cancer Institute SNP500 database.
RESULTS: In our MDS population, the -308A/A genotype of the TNFalpha gene and the TGFbeta1 allele +29T and genotype +29T/T, each associated with higher levels of expression, were overrepresented in our MDS population.
CONCLUSIONS: Polymorphisms associated with increased expression in the cytokines TNFalpha and TGFbeta1 are overrepresented in the MDS population suggesting that increased TNF-alpha and TGF-beta1 activity may contribute to the susceptibility and/or pathogenesis of MDS. Further studies with larger sample sizes are warranted to confirm our observation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18081437     DOI: 10.5858/2007-131-1789-PITATA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  10 in total

1.  Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.

Authors:  Li Zhou; Christine McMahon; Tushar Bhagat; Cristina Alencar; Yiting Yu; Melissa Fazzari; Davendra Sohal; Christoph Heuck; Krishna Gundabolu; Chun Ng; Yongkai Mo; Wa Shen; Amittha Wickrema; Guanghui Kong; Ellen Friedman; Lubomir Sokol; Ioannis Mantzaris; Giannis Mantzaris; Andrea Pellagatti; Jacqueline Boultwood; Leonidas C Platanias; Ulrich Steidl; Lei Yan; Jonathan M Yingling; Michael M Lahn; Alan List; Markus Bitzer; Amit Verma
Journal:  Cancer Res       Date:  2010-12-28       Impact factor: 12.701

Review 2.  Inflammatory signals regulate hematopoietic stem cells.

Authors:  Megan T Baldridge; Katherine Y King; Margaret A Goodell
Journal:  Trends Immunol       Date:  2011-01-11       Impact factor: 16.687

3.  MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-β pathways.

Authors:  Minyoung Youn; Haigen Huang; Cheng Chen; Sharon Kam; Mark C Wilkes; Hee-Don Chae; Kunju J Sridhar; Peter L Greenberg; Bertil Glader; Anupama Narla; Shuo Lin; Kathleen M Sakamoto
Journal:  Blood Adv       Date:  2019-09-24

4.  Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.

Authors:  Li Zhou; Aaron N Nguyen; Davendra Sohal; Jing Ying Ma; Perry Pahanish; Krishna Gundabolu; Josh Hayman; Adam Chubak; Yongkai Mo; Tushar D Bhagat; Bhaskar Das; Ann M Kapoun; Tony A Navas; Simrit Parmar; Suman Kambhampati; Andrea Pellagatti; Ira Braunchweig; Ying Zhang; Amittha Wickrema; Satyanarayana Medicherla; Jacqueline Boultwood; Leonidas C Platanias; Linda S Higgins; Alan F List; Markus Bitzer; Amit Verma
Journal:  Blood       Date:  2008-05-12       Impact factor: 22.113

5.  miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling.

Authors:  Tushar D Bhagat; Li Zhou; Lubomir Sokol; Rachel Kessel; Gisela Caceres; Krishna Gundabolu; Roni Tamari; Shanisha Gordon; Ioannis Mantzaris; Tomasz Jodlowski; Yiting Yu; Xiaohong Jing; Rahul Polineni; Kavi Bhatia; Andrea Pellagatti; Jacqueline Boultwood; Suman Kambhampati; Ulrich Steidl; Cy Stein; Wenjun Ju; Gang Liu; Paraic Kenny; Alan List; Markus Bitzer; Amit Verma
Journal:  Blood       Date:  2013-02-06       Impact factor: 22.113

6.  Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome.

Authors:  Wanlong Ma; Hagop Kantarjian; Ke Zhang; Xi Zhang; Xiuqiang Wang; Clifford Chen; Amber C Donahue; Zhong Zhang; Chen-Hsiung Yeh; Susan O'Brien; Guillermo Garcia-Manero; Neil Caporaso; Ola Landgren; Maher Albitar
Journal:  BMC Med Genet       Date:  2010-11-16       Impact factor: 2.103

7.  Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes.

Authors:  Toshio Asayama; Hideto Tamura; Mariko Ishibashi; Yasuko Kuribayashi-Hamada; Asaka Onodera-Kondo; Namiko Okuyama; Akiko Yamada; Masumi Shimizu; Keiichi Moriya; Hidemi Takahashi; Koiti Inokuchi
Journal:  Oncotarget       Date:  2017-10-04

8.  Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome.

Authors:  J X Zou; D E Rollison; D Boulware; D-T Chen; E M Sloand; L V Pfannes; J J Goronzy; F Bai; J S Painter; S Wei; D Cosgrove; A F List; P K Epling-Burnette
Journal:  Leukemia       Date:  2009-03-12       Impact factor: 12.883

9.  Gastric carcinoma subsequent to myelodysplastic syndrome with t (1; 19) chromosome translocation: A rare case report and its potential mechanisms.

Authors:  Wenqing Yu; Gaoyang Chen; Yunpeng Sun; Sujun Gao; Wei Li; Jiuwei Cui; Jingnan Sun
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

10.  Interaction between Herpes Virus Infections and IL10 and Risk of Bone Marrow Suppression.

Authors:  R Yaghobi; F Alizadeh; A Khodavandi
Journal:  Int J Organ Transplant Med       Date:  2018-08-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.